Ocutrx Harnesses the Power of AR for Vision Correction

A start-up is using the power of augmented reality to help patients plagued with Advanced Macular Degeneration (AMR). Ocutrx Vision Technologies has developed the Oculenz AR glasses and has successfully completed the first pre-pilot trial for the technology. Michael Freeman, Ocutrx founder and CEO, told MD+DI the company was “creating a medical device that helps correct macular degeneration. We’re in the generic category, so we’re 510(k) exempt on the regulatory pathway. We have other uses like amblyopia and in the surgery room that will require a regulatory pathway.” The Patient Study was assisted by Scott Hewitt, CCRC and Deborah Hardison, COMT. Mean age of the subjects was 68 (54-76). The best-corrected acuity was from less than 20/200 with near (or no correction) improving to 20/63 with the Oculenz ARwear without magnification. Mean CPS improved from 0.96 logMAR (L/R) with near or no correction to 0.61 (L) and 0.58 (R) logMAR with the Oculenz ARwear at no magnification. Improvement ranged up to 5 lines on the logMAR chart without magnification. All subjects had difficulty reading and most subjects had not been able to read for years prior to wearing Oculenz. All subjects were able to read at a standard reading pace at 30-point type (J-16); with some reading down to 12-point type (J-10) in just one session wearing the Oculenz. These results suggest that with “neuro-adaptationâ&#...
Source: MDDI - Category: Medical Devices Authors: Tags: Digital Health Source Type: news